Article

Biochanin-A inhibits the activity of androgen receptor mutants to suppress the development of prostate cancer

2025-05-30

Abstract excerpt

<title>Abstract</title> <p>Androgen and androgen receptor (AR) were essential for the development of prostate cancer. Biochanin-A (BCA) has been reported to inhibit androgen synthesis to overcome resistance to abiraterone and enzalutamide. However, its direct function on androgen receptor remains unrevealed. Here, we investigated the affinity and biological effect of BCA to different AR mutants to find potential...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 677da83a-3abb-5113-9a31-2803190dd03a
DOI: 10.21203/rs.3.rs-6311929/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Biochanin-A inhibits the activity of androgen receptor mutants to suppress the development of prostate cancerDOI 10.21203/rs.3.rs-6311929/v1Read

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerSemantic proximity Read

Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.Semantic proximity Read

In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancerSemantic proximity Read

A novel small-molecule androgen receptor antagonist selective for the T878A-mutant AR in prostate cancer therapy.Semantic proximity Read

A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.Semantic proximity Read

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.Semantic proximity Read

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.Semantic proximity Read

Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.Semantic proximity Read

5β-Dihydrotestosterone reveals a mutant androgen receptor vulnerability in prostate cancerSemantic proximity Read

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate CancerSemantic proximity Read

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer PatientsSemantic proximity Read

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancerSemantic proximity Read